Aims and objectives. To explore the prevalence of decreased appetite and factors associated with appetite among patients with stable heart failure.
Introduction
Heart failure (HF) is a progressive and symptomatic syndrome, characterized by lifelong medical treatment and great health care needs. HF affects around 2% of the population in developed countries, and the prevalence is particularly high in older people. At age >65, the estimated prevalence is about 10% (McMurray et al. 2012 , Go et al. 2014 . In recent decades, the treatment of HF has undergone major improvements. However, the syndrome is still associated with poor prognosis, especially in patients with undernutrition (Bonilla-Palomas et al. 2011) . Decreased appetite may play a role in the development of undernutrition. However, the underlying causes for decreased appetite in HF have mainly been studied from a pathophysiological perspective and are not fully clear (Fudim et al. 2011) . Decreased appetite among patients with HF is a problematic and unrecognized issue, and a better understanding of its manifestations will provide valuable support in efforts to prevent or delay undernutrition among patients with HF.
Background
Appetite is a complex phenomenon that contributes to an individual's body weight. Loss of appetite, defined as the reduced desire to eat, may vary due to psychobiological changes and environmental factors (Muscaritoli et al. 2010) . The phenomenon becomes more complicated in cases of chronic illness, and it can be hypothesized that appetite may interplay with a series of components. Older age can possibly contribute to decreased appetite. In chronic conditions, studies have shown that patients >60 years report worsened appetite compared to younger patients (Cheung et al. 2011) . Among the elderly, the aeging process may cause poor appetite due to a disturbance of appetite hormones (Malafarina et al. 2013) . Impaired health status may also cause decreased appetite; a study among older people living in nursing homes showed that patients with dementia, 4 depression, and gastrointestinal problems ran twice the risk of having poor appetite compared to those not affected by these barriers (Landi et al. 2013) . However, appetite in the context of older people and in chronic conditions needs to be further explored.
Currently, there are no available standard treatments to improve poor appetite in HF or any other chronic disease (von Haehling & Anker 2014) . One possible reason is that appetite is a complex phenomenon and that it is difficult to measure due to a lack of validated self-reported instruments.
Furthermore, a small study (n=135) has showed that appetite may be worse in patients with HF compared to healthy older people (Lennie et al. 2006) . In addition, it seems like depression negatively affects appetite. A study among 572 hospitalized older patients with HF showed that decreased appetite is more prominent among those with depressive symptoms (Lesman- Leegte et al. 2006) . The role of cognitive function and insomnia for appetite is not clear, despite other studies having shown that cognitive function (Orsitto et al. 2009 , Farid et al. 2013 ) and insomnia (Westergren et al. 2013) are associated with undernutrition. With regard to this, poor appetite may possibly contribute to undernutrition as well. Since the cardinal symptoms of HF include breathlessness and fatigue, it is possible that these symptoms, as well as side effects of medical treatment and gastrointestinal oedema, also play a role in reduced appetite.
Based on few available studies, we hypothesised that the influence on appetite is multifactorial, and that demographic, psychosocial and medical factors may interplay. Accordingly, an expanded knowledge on the scope of decreased appetite and possible contributing factors in HF may guide health care professionals to prevent and treat undernutrition. Thus, the aim of this study was to explore the prevalence of decreased appetite and the factors associated with appetite among patients with stable HF.
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Methods
Design and sample
This Swedish multicenter cross-sectional study was carried out between 2009 and 2012. In accordance with the Declaration of Helsinki, the patients received oral and written study information and provided informed consent. Approval was obtained by the Regional Ethical Review Board in Linköping (study code: M222-08/T81-09).
Patients with stable HF were consecutively recruited from three outpatient HF clinics at one university hospital and two county hospitals. The inclusion criteria were ≥18 years old, having mild to severe left ventricle systolic dysfunction and presence of HF symptoms. Patients on dialysis due to renal failure, and/or short life expectancy due to other diseases than HF, were excluded. The recruitment was performed during a regular HF outpatient visit. A total of 316 patients were invited to participate in the study, of whom 186 accepted (59%) ( Table 1 ). This sample size was justified by a priori power analysis, conducted to determine the minimum sample size that would be acceptable for a multiple linear regression model. The calculation was based on a regression model including 13 independent variables, medium effect size (ƒ 2 =0.15), a significance level of 0.05 and a power of 0.90. To detect a R 2 deviation from 0, the minimum sample size was estimated to 162
individuals. The non-participants were significantly older than the participants (t(313)=3.64, p<0.001), but there was no significant difference regarding sex (χ 2 (1)=0.10, p=0.701).
Procedure and data collection
The study was conducted during two visits, first at the hospitals and then in the patients' homes.
During the first visit, data collection included a review of the patients' medical records (diagnosis, comorbidity, and medical treatment). A physical examination (six minutes' walk test) was also performed to assess HF symptoms according to New York Heart Association (NYHA) functional classification (McMurray et al. 2012) . The patients were instructed to walk 30 m back and forth for six minutes. After that, the walking distance in meters was calculated. Longer distance implies better functional capacity (Rostagno & Gensini 2008) . In addition, assessment of anthropometrics (Body Mass Index (BMI), waist-to-hip ratio) and blood samples (albumin) was performed using principles of nutritional assessment (Gibson 2005) et al. 2012) . Comorbidity was assessed with the Charlson Comorbidity Index (CCI). In the CCI, nineteen diseases are divided into four weighted classification groups (1, 2, 3, and 6). Based on these classifications, comorbidities are summed to an index. Higher scores indicate more problems with comorbidity (Charlson et al. 1987) . A questionnaire was also handed out for patients to complete at home. This included demographic questions and validated self-rating scales to assess appetite, symptoms of depression, self-perceived health, daytime sleepiness, and insomnia.
The purpose of the home visit was to collect the questionnaires and assess global cognitive function using the Mini Mental State Examination (MMSE). This screening tool was developed to assess cognitive function and contains questions about orientation with regard to time and place, memory by repeating words, attention by counting or spelling backwards, ability to recall previously mentioned words, and language tests (Folstein et al. 1975) . The maximum score is 30, where a score of 24-30 indicates no cognitive impairment and a lower score, usually with a cut-off level of 7 ≤23, is considered as mild to severe cognitive impairment (Tombaugh & McIntyre 1992) . In this study, MMSE was used as a continuous varable.
The questionnaires
Appetite was assessed by The Council on Nutrition Appetite Questionnaire (CNAQ) (Wilson et al. 2005) . The instrument which has been validated in HF populations (Andreae et al. 2015 ) includes a scale with eight items, each rated on a five-point scale. The total score ranges from 8-40, with lower scores indicating poorer appetite, and a CNAQ score ≤28 indicating a risk of significant weight loss over a six-month time period. In this study, internal consistency reliability was satisfactorily high; Cronbach´s α was 0.74.
The Patient Health Questionnaire (PHQ-9) was used to measure symptoms of depression.
The items grade patients' experiences of bothersome symptoms of depression in the last two weeks.
A total of 9 items are rated on a four-point Likert-type scale, ranging from the lowest score "not at all" (0) to the worst "nearly every day" (3). The total score ranges from 0-27; (0-4) none to minimal, (5-9) mild, (10-14) moderate, (15-19) moderately severe and (20-27) severe depression (Kroenke et al. 2001) . In this study, Cronbach´s α was 0.81.
The EuroQol EQ-5D was used to measure self-perceived health. The patients were asked to rate five dimensions including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension consists of three levels: (level 1) no problem, (level 2) some problems and (level 3) extreme problems. In this study, all five dimensions were converted to the EQ-5D three-level index (EQ-5D-3L index), with higher scores indicating better self-perceived health. EQ VAS was used to measure the current state of health on a 0-100 thermometer scale, 8 where zero indicates the worst imaginable state of health and 100 the best imaginable state of health (Brooks 1996) .
The Epworth Sleepiness Scale (ESS) was developed to measure daytime sleepiness. The initial item deals with the likeliness of dozing off or falling asleep in different situations, e.g., when
reading or watching TV. The eight items in the ESS are answered on a four-point Likert-type scale with a possible score between 0-24, where a higher score indicates more problems with daytime sleepiness (Johns 1991). Cronbach´s α in this study was 0.75.
The Minimal Insomnia Symptom Scale (MISS) was developed to assess sleeping difficulties. Three items covering difficulties falling asleep, night awakening and not being rested by sleep are answered on a five-point Likert-type scale. The total score ranges from 0, indicating no problem at all, to a high of 12, indicating major problems. A total score of ≥6 indicates increased risk of insomnia (Broman et al. 2008) . Cronbach´s α in this study was 0.80.
Analysis
Descriptive statistics were used to describe sample characteristics and study variables. According to the level and distribution of the data, continuous variables are presented with median and quartiles and categorical variables with frequencies and percentages. Mean and standard deviation was used when appropriate. Chi-square statistics, Mann-Whitney U test and independent sample ttests were performed to compare different sample characteristics for patients at risk of and at no risk of weight loss according to CNAQ, i.e., scores ≤28 or >28.
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Spearman´s rank correlation coefficient (rho) was used to explore bivariate associations between appetite and the predictor variables, i.e., sex, age, cohabitation, functional capacity (NYHA-class), comorbidity (CCI), myocardial stress (BNP), symptoms of depression (PHQ-9), self-perceived health (EQ-5D and EQ VAS), daytime sleepiness (ESS), insomnia (MISS), cognitive function (MMSE) and medical treatment (beta-blocker, angiotensin-covering-enzyme-inhibitor and angiotensin-receptor-blocker).
To further explore the association between appetite and the predictor variables, all variables in the correlation analysis with a probability value <0.05 were included in the multiple linear regression analysis, which was performed in a stepwise procedure (backward selection). 
Results
Patient characteristics
A description of the sample characteristics is presented in Table 2 . A total of 186 patients, 130 men and 56 women, completed the study. Median age was 72 years (IQR=65-78), and the majority had HF symptoms corresponding to NYHA class II (61%). Most of the patients were treated with conventional HF medications, i.e., beta-blockers (94%), ACE-inhibitors (60%) and angiotensinreceptor-blockers (41%). The majority had a normal nutrition status with BMI >20kg/m 2 (n=182) and albumin ≥30g/l (n=180). Most patients had normal cognitive function, although symptoms of depression (42%) and insomnia (39%) were highly prevalent.
Appetite
The results of this study show that 71 (38%) of the patients had poor appetite, i.e., CNAQ scores ≤28, with a risk of developing future weight loss. The CNAQ scores ranged between 17-37 with a median value of 30 (IQR=27-31) ( Table 2) .
Bivariate associations
Nine variables correlated significantly with appetite (Table 3) . Older age, living alone, decreased functional capacity (i.e., higher NYHA class), worse self-perceived health (both EQ-5D index and EQ VAS), higher level of symptoms of depression, insomnia, decreased cognitive function and insufficient medical treatment were associated with lower levels of appetite. Depressive symptoms was the factor that correlated the strongest with appetite (rho=-0.422, p<0.001). Neither sex, comorbidity, myocardial stress (BNP) nor daytime sleepiness correlated significantly with appetite.
Multivariate associations
Overall, the stepwise multiple regression analyses showed that age, symptoms of depression, insomnia, cognitive function and medical treatment were significantly associated with appetite (Table 4) 
Discussion
This study aimed to explore decreased appetite prevalence and factors among patients with stable HF. The findings showed that decreased appetite is a major problem among patients with HF.
Furthermore, appetite was associated with age, symptoms of depression, insomnia, cognitive function and pharmacological treatment.
More than one third of the patients (38%) reported appetite levels that put them at risk of weight loss. The prevalence of decreased appetite in this study was, however, lower than has been observed in other chronic conditions, for example kidney disease (50%) (Gama-Axelsson et al. 2013) and cancer (88%) (Liu et al. 2013) . A previous study by Song et al. (2010) reported that approximately 60% of patients with HF had poor appetite. The prevalence discrepancy between Song et al. and the present study may be due to appetite being assessed with different instruments. Another explanation may be that participants in the present study had stable HF and were recruited from 12 outpatient clinics. This can be compared with Song et al. (2010) who recruited patients hospitalised with decompensated HF, which may be associated with even more impaired appetite. As decreased appetite is associated with undernutrition and worsened prognosis (Landi et al. 2013 , Malafarina et al. 2013 , these findings need to be addressed in the care of patients with HF. In particular, efforts should be made to identify patients at risk of decreased appetite, for example by structured appetite assessments. Standard treatment to improve appetite is still lacking (von Haehling & Anker 2014).
Therefore, health care professionals should offer individualised dietary advice to help patients with poor appetite maintain weight and prevent undernutrition, for example by using energy and protein rich food and nutritional supplements to reach their daily energy intake. Patients can also be recommended to divide their daily food intake into smaller and more frequent meals. For this, a nutritional care plan for setting nutritional goals may be helpful. Despite the large share of patients with poor appetite in this study, the majority were well nourished. One explanation may be that the participants had less HF symptoms and that most of them were treated with conventional HF medications, which have been shown to protect against undernutrition (Anker et al. 2003) .
Several factors in the present study were found to be associated with appetite: age, symptoms of depression, insomnia, cognitive function and pharmacological treatment. Older age was found to be associated with lower levels of appetite. This corresponds with a study by Cheung et al. (2011) , which showed that decreased appetite was more common among the older compared to younger people. Furthermore, the aeging process may contribute to poor appetite due to hormonal changes (Landi et al. 2013) . It has been shown that the appetite hormone ghrelin was reduced in older people, which may have negative effects on gastric emptying and gut motility (Malafarina et al. 2013 ).
Related to older age, lower levels of cognitive function were associated with decreased appetite.
To our knowledge, no previous study has explored the association between cognitive function and appetite. A study among 623 older hospitalised patients with mild cognitive impairment showed that 58% were at risk of becoming undernourished (Orsitto et al. 2009 ). Nutrition status in that study was measured by the Mini Nutritional Assessment (MNA), a screening tool for determining the risk of undernutrition in hospital care, not appetite. Similar associations between impaired cognitive function and body weight have been observed in patients with cardiovascular disease as well (Farid et al. 2013) .
Neither age nor cognitive function are clear targets for interventions. In order to prevent undernutrition, particularly in these groups, health care professionals should routinely assess and discuss appetite in HF care. As the CNAQ has been shown to have acceptable measurement properties in patients with HF (Andreae et al. 2015) , structured assessments with this tool can be useful for identifying patients at risk of weight loss. Discussions about appetite and dietary habits with patients and family members may serve for individualised nutrition advice and interventions.
Patients with decreased appetite in combination with signs of undernutrition, for example weight loss, should preferably be referred to a dietician for expert advice and treatment.
In contrast to age and cognitive function, symptoms of depression, insomnia and pharmacological treatment are factors more suitable for interventions. Findings from this study showed that higher levels of symptoms of depression are associated with poor appetite. These findings corresponds with other studies that have demonstrated that symptoms of depression constitute a barrier for nutrition intake (Lennie et al. 2006 , Lesman-Leegte et al. 2006 . A study by Lesman-Leegte et al. (2006) showed that poor appetite was more common among depressive patients than in nondepressive patients with HF, 68% vs. 49% respectively. The prevalence of poor appetite in this study was nearly half of that. A possible explanation for this might be that the majority of the participants had less HF symptoms and less comorbidity. Another explanation is that appetite in this study was assessed by the CNAQ, which is in contrast to Lesman-Leegte et al. (2006) , who determined appetite through interviews. Another study on 114 older nursing home residents also showed a significant association between symptoms of depression and appetite, but to a lesser extent (Smoliner et al. 2009 ). As depression can be a barrier for performing adequate nutritional self-care activities, health care professionals should routinely screen for and treat symptoms of depression (Lainscak et al. 2011) .
A large share of the patients in this study reported problems with insomnia, which was associated with decreased appetite. Sleep disturbance might negatively affect daily life with both psychological and physical consequences, such as daytime tiredness (Redeker et al. 2010) . The consequences of tiredness might lead to disrupted food routines and a potential risk of meals being postponed until a later time, or in the worst case being skipped altogether. That can in turn lead to decreased food intake and development of undernutrition. To our knowledge, there are no previous studies that have specifically investigated insomnia and appetite in patients with HF. Further studies are needed for a better understanding of this association.
In this study, BMI was assessed in order to describe nutrition status. Studies have shown an association between low BMI, decreased appetite and unintentional weight loss (Westergren et al. 2009 ). Therefore, assessing BMI and self-perceived appetite may be of value for determining the risk of undernutrition. However, in cases of acute deterioration of HF, BMI can be misleading as decompensated HF often leads to fluid retention and weight gain (Gibson 2005) . In this study, the patients were stable at inclusion, but they might have had oedema.
Limitations
This study has some limitations that need to be considered. Most importantly, the study had a crosssectional design, which limits the possibilities to draw any causal conclusions regarding the relationship between the identified factors and appetite level. This addresses the need for further prospective studies, for example trajectories of appetite over time and associated factors. In accordance with other HF studies (Näsström et al. 2014) , there was a large number of nonparticipants. This can be explained by the fact that many patients with HF suffer a high symptom burden, often combined with old age, which makes it difficult to participate in research studies. Another limitation is that the sample had a history of predominantly mild to moderate HF, which makes it difficult to generalise the findings to the most symptomatic patients in NYHA class IV.
There are different methods to assess appetite and previous studies have mainly used single items or scales, such as the appetite item in Mini Nutritional Assessment (MNA), visual analogue scale (VAS), numerical rating scale (NRS) or verbal rating scale (VRS). However, appetite is a complex construct that not easily can be measured with a single item. Of this reason appetite was measured with the CNAQ in this study, which have shown good measurement properties among patients with HF (Andreae et al. 2015) . This resulted in difficulties comparing the finding with other studies.
Appetite is not a variable likely to generate more socially desirable responding. However, response bias related to the home visit cannot be excluded. Participants completed the questionnaire at home; they were instructed to do it on their own and to follow the provided instructions. However, we 16 could not control for if someone else was consulted when they completing the survey. Another limitation was the small number of assessments to determine nutritional status. However, both BMI (Kondrup et al. 2003) and albumin (McMurray et al. 2012) have been described as potential assessment tools in order to detect risk of undernutrition. The mean age in this study was some years lower than the general HF population according to the Swedish HF registry (Lund et al. 2014 ). Due to the gender distribution also not being equal, this may limit the generalisability of the findings to the oldest and women.
Conclusion
This study adds new insights into appetite prevalence in patients with stable HF. Decreased appetite is a significant problem, associated with demographic, psychosocial and medical factors. These findings need to be confirmed by further studies, preferably with prospective designs.
Relevance to clinical practice
Decreased appetite plays an important role in the development of undernutrition and is therefore a significant clinical problem. Early management of decreased appetite may prevent or delay undernutrition. This study underlines that appetite should be given special attention in older patients with HF, especially those with decreased cognitive function, symptoms of depression, sleeping difficulties and suboptimal HF treatment. In clinical practice, health care professionals should routinely assess appetite and especially focus on the older frail patients with HF and multimorbidity. All patients with decreased appetite should be offered nutritional advice and support to improve nutritional self-care in order to maintain their weight and prevent undernutrition. As appetite is a complex phenomenon, assessments can be facilitated by using a short, validated self-rating scale such as the CNAQ. Besides patients themselves and health care professionals, it is important that also family members and significant others pay attention to signs of decreased appetite and undernutrition and actively participate in interventions to improve nutrition. The family plays a very important role in nutritional and eating habits of the patient and should therefore routinely be involved in the HF care. Participants who fulfilled the study inclusion criteria, and those who declined to participate at each hospital.
University hospital Fulfilled inclusion criteria n=124
Declined to participate n=50
County hospital
Fulfilled inclusion criteria n=26
Declined to participate n=1
County hospital
Fulfilled inclusion criteria n=166
Declined to participate n=79
The final number of participants in the study University hospital n=74
County hospital n=25
County hospital n=87 a Having optimal dose of one or both beta-blocker and angiotensin-covering-enzymeinhibator/angiotensin-receptor-blocker.
Total n=186
